FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2136713932> ?p ?o ?g. }

• W2136713932 abstract "Cystic fibrosis (CF) has a complex and chronic manifestation, with the severity and types of symptoms differing widely from person to person depending on their specific genetic mutation, their environment and their genetic background. Individuals with CF have treatment plans aimed at ameliorating the debilitating symptoms of their disease, including difficulties in breathing, recurrent lung infections and digestive disorders. The year 2012 marked a turning point for certain eligible CF patients — KALYDECO™ was approved as a therapy for a small group of CF patients exhibiting the G551Dmutation [1] and eight other rare CFTR mutations in the CFTR gene. KALYDECO ™, whose active principle is the potentiator Ivacaftor, acts to directly repair the defect in CFTR channel activity, instead of a symptom-based approach traditionally used to treat CF patients. The positive clinical effects of this medication have been remarkable and life-changing for this small CF patient group. The major CF-causing mutation, F508del, present on at least one allele in 85% of CF subject cases [2], causes multiple defects in protein folding, assembly, and functional expression and hence, improvement by pharmacological modulators presents a significant challenge.The CF community was excited to learn that lung function was observed in a Phase III clinical trial [3] of Ivacaftor plus the compound Lumacaftor, a “corrector” compound that acts to partially improve F508del-CFTR biosynthesis, processing and stability [4]. This co-therapy (Orkambi™) was recently approved by the FDA as a treatment for CF patients who are homozygous for the major mutation. However, heterogeneity in the clinical response to Orkambi™ by this patient cohort, highlights the importance of developing novel compounds in order to effectively treat everyone with this mutation. The research community recognizes the need to identify more effective compounds targeting the defects caused by F508del-CFTR (and other mutations not currently targeted in drug discovery programs), to develop in-vitro tools to stratify responsive patients, and to identify compounds for rational alternative targets in order to provide companion therapies [5].Following from an initial seminar in 2014 [6] which addressed CFTR functional measurements in human models for diagnosis, prognosis and personalized therapy, this preconference seminar to the ECFS Basic Science Conference was held in Albufeira (Portugal) on March 25–28, 2015. Novel drug screens conducted using unique, mechanism-based discovery platforms were discussed. Strategies for identifying small molecules that target epithelial channels (other than CFTR) known to modulate epithelial fluid transport and potentially compensate for the lack of CFTR function were described. Such strategies may be advantageous in therapy development for patients bearing mutations that are not directly amenable to pharmacological correction. Further, the need to complement ion channel activity studies with measurements of more complex epithelial functions, i.e., ciliary beating and mucus rheology in order to optimize the capacity of in-vitro assays to predict clinical efficacy was discussed. Finally, a EU screening facility that will enhance progress in drug discovery was described. This facility will engage with scientists to implement the next generation of drug discovery platforms and provide effective mutation and patient-targeted therapies." @default.
• W2136713932 created "2016-06-24" @default.
• W2136713932 creator A5014956829 @default.
• W2136713932 creator A5027077813 @default.
• W2136713932 creator A5042356327 @default.
• W2136713932 creator A5047681000 @default.
• W2136713932 creator A5059886022 @default.
• W2136713932 creator A5082533691 @default.
• W2136713932 creator A5082884953 @default.
• W2136713932 creator A5085975282 @default.
• W2136713932 date "2015-11-01" @default.
• W2136713932 modified "2023-10-01" @default.
• W2136713932 title "Finding new drugs to enhance anion secretion in cystic fibrosis: Toward suitable systems for better drug screening. Report on the pre-conference meeting to the 12th ECFS Basic Science Conference, Albufeira, 25–28 March 2015" @default.
• W2136713932 cites W1536852491 @default.
• W2136713932 cites W1589654967 @default.
• W2136713932 cites W1609607589 @default.
• W2136713932 cites W1751444511 @default.
• W2136713932 cites W1975983158 @default.
• W2136713932 cites W1976507289 @default.
• W2136713932 cites W1978811535 @default.
• W2136713932 cites W1981193117 @default.
• W2136713932 cites W1983746433 @default.
• W2136713932 cites W1987901119 @default.
• W2136713932 cites W1988068284 @default.
• W2136713932 cites W1997114875 @default.
• W2136713932 cites W2015811319 @default.
• W2136713932 cites W2022634662 @default.
• W2136713932 cites W2022941489 @default.
• W2136713932 cites W2023122863 @default.
• W2136713932 cites W2029151587 @default.
• W2136713932 cites W2031948962 @default.
• W2136713932 cites W2035131077 @default.
• W2136713932 cites W2039462910 @default.
• W2136713932 cites W2041857700 @default.
• W2136713932 cites W2044380511 @default.
• W2136713932 cites W2049314578 @default.
• W2136713932 cites W2050264979 @default.
• W2136713932 cites W2051836609 @default.
• W2136713932 cites W2054338637 @default.
• W2136713932 cites W2054716883 @default.
• W2136713932 cites W2055953510 @default.
• W2136713932 cites W2065575866 @default.
• W2136713932 cites W2071407356 @default.
• W2136713932 cites W2078078890 @default.
• W2136713932 cites W2078571865 @default.
• W2136713932 cites W2082372749 @default.
• W2136713932 cites W2085652695 @default.
• W2136713932 cites W2092868876 @default.
• W2136713932 cites W2095655618 @default.
• W2136713932 cites W2099916828 @default.
• W2136713932 cites W2103879666 @default.
• W2136713932 cites W2111720163 @default.
• W2136713932 cites W2132756075 @default.
• W2136713932 cites W2135363031 @default.
• W2136713932 cites W2135610502 @default.
• W2136713932 cites W2140868856 @default.
• W2136713932 cites W2145786361 @default.
• W2136713932 cites W2147868143 @default.
• W2136713932 cites W2151829259 @default.
• W2136713932 cites W2151837778 @default.
• W2136713932 cites W2156294657 @default.
• W2136713932 cites W2158706178 @default.
• W2136713932 cites W2159361777 @default.
• W2136713932 cites W2159964828 @default.
• W2136713932 cites W2160859910 @default.
• W2136713932 cites W2161125214 @default.
• W2136713932 cites W2171342153 @default.
• W2136713932 cites W2202718035 @default.
• W2136713932 cites W2301131921 @default.
• W2136713932 cites W2320721555 @default.
• W2136713932 cites W2406591348 @default.
• W2136713932 cites W51293338 @default.
• W2136713932 doi "https://doi.org/10.1016/j.jcf.2015.10.001" @default.
• W2136713932 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4786369" @default.
• W2136713932 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26474804" @default.
• W2136713932 hasPublicationYear "2015" @default.
• W2136713932 type Work @default.
• W2136713932 sameAs 2136713932 @default.
• W2136713932 citedByCount "2" @default.
• W2136713932 countsByYear W21367139322016 @default.
• W2136713932 countsByYear W21367139322020 @default.
• W2136713932 crossrefType "journal-article" @default.
• W2136713932 hasAuthorship W2136713932A5014956829 @default.
• W2136713932 hasAuthorship W2136713932A5027077813 @default.
• W2136713932 hasAuthorship W2136713932A5042356327 @default.
• W2136713932 hasAuthorship W2136713932A5047681000 @default.
• W2136713932 hasAuthorship W2136713932A5059886022 @default.
• W2136713932 hasAuthorship W2136713932A5082533691 @default.
• W2136713932 hasAuthorship W2136713932A5082884953 @default.
• W2136713932 hasAuthorship W2136713932A5085975282 @default.
• W2136713932 hasBestOaLocation W21367139321 @default.
• W2136713932 hasConcept C104317684 @default.
• W2136713932 hasConcept C12125453 @default.
• W2136713932 hasConcept C126322002 @default.
• W2136713932 hasConcept C164718446 @default.
• W2136713932 hasConcept C187212893 @default.
• W2136713932 hasConcept C2776169613 @default.
• W2136713932 hasConcept C2776502428 @default.
• W2136713932 hasConcept C2776938444 @default.
• W2136713932 hasConcept C2778428886 @default.

• next